Portal de Periódicos da CAPES

Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study

2024; Future Medicine; Volume: 20; Issue: 32 Linguagem: Inglês

10.1080/14796694.2024.2385287

1744-8301

Juan Martín-Liberal, Elena Garralda, Jesús García-Donás, J.J. Soto Castillo, Alberto Mussetti, Carles Codony, Silvia Martin Lluesma, Susana Muñoz, Vladimir Galvao, Júlia Lostes, M. Rotxes, Cristina Prat‐Vidal, Jara Palomero, Ainhoa Muñoz, Rafael Moreno, Xavier García del Muro, Anna Sureda, Ramón Alemany, Alena Gros, Josep M. Piulats,

interferon and immune responses

The SWI/SNF complex is a chromatin remodeling complex comprised by several proteins such as SMARCA4 or SMARCB1. Mutations in its components can lead to the development of aggressive rhabdoid tumors such as epithelioid sarcoma, malignant rhabdoid tumor or small cell carcinoma of the ovary hypercalcemic type, among others. These malignancies tend to affect young patients and their prognosis is poor given the lack of effective treatments. Characteristically, these tumors are highly infiltrated by TILs, suggesting that some lymphocytes are recognizing tumor antigens. The use of those TILs as a therapeutic strategy is a promising approach worth exploring. Here, we report the clinical protocol of the TILTS study, a Phase II clinical trial assessing personalized adoptive cell therapy with TILs in patients affected by these tumor types.